secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001193125-25-039219
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Personalis reports FY24 revenue $84.6M (+15% YoY); provides FY25 guidance with $80-90M revenue, net loss ~$85M
--------------------------------------------------------------------------------

- FY24 revenue $84.6M (+15% YoY); net loss $81.3M vs $108.3M in FY23; cash $185M including $50M Merck investment.
- Q4 revenue $16.8M (-15% YoY); delivered 1,441 molecular tests in Q4 (+52% QoQ); FY24 tests 3,285 vs 177 in FY23.
- Guidance: FY25 revenue $80-90M, gross margin 21-23%, net loss ~$85M, cash usage $75-80M (up from $47M in FY24).
- Business highlights: submitted for Medicare coverage in early-stage breast cancer; multi-year Moderna extension; expanded Tempus deal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000119312525039219/0001193125-25-039219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000119312525039219/d933582d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-039219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer